Molecular epidemiology and novel combinations of auxotype, serovar, and plasmid content in tetracycline-resistant Neisseria gonorrhoeae isolated in Canada

1990 ◽  
Vol 36 (1) ◽  
pp. 64-67 ◽  
Author(s):  
Jo-Anne R. Dillon ◽  
Maria Carballo
Keyword(s):  
Neisseria Gonorrhoeae ◽  
Molecular Epidemiology ◽  
Disease Control ◽  
Key Words ◽  
Tetracycline Resistance ◽  
Resistance Determinant ◽  
Plasmid Content ◽  
Resistance Plasmid ◽  
Canadian Provinces ◽  
First Time

Between October 1987 and June 1989, 84 isolates of Neisseria gonorrhoeae carrying the TetM resistance determinant (TRNG) were received at the Laboratory Centre for Disease Control, Ottawa, from six Canadian provinces and were characterized into classes based on auxotype, serovar and plasmid content. One-fifth (17/84) of the TRNG were also penicillinase producing (PPNG). The PPNG–TRNG isolates comprised six classes based on auxotype, serovar, and plasmid content. Most (16/17) PPNG–TRNG carried 3.2-MDa β-lactamase plasmids and the 25.2-MDa TetM-containing plasmid. We report, for the first time, the association of a 4.5-MDa β-lactamase plasmid with the 25.2-MDa plasmid in a clinical TRNG isolate. Non-PPNG TRNG isolates comprised 11 classes based on auxotype, serovar, and plasmid content, including two previously unreported auxotype–serovar classes, P/IB-26 and P/IB-20. Key words: Neisseria gonorrhoeae, tetracycline resistance, plasmid, epidemiology.

Antibiotic resistance, plasmid content and auxotypes of Neisseria gonorrhoeae in Greece

1988 ◽  
Vol 21 (5) ◽  
pp. 571-579 ◽  
Author(s):  
L. Mavrommati ◽  
E. Tzetepi ◽  
A. Sima ◽  
G. Tzanakaki ◽  
A. Kokia ◽  
...  
Keyword(s):  
Antibiotic Resistance ◽  
Neisseria Gonorrhoeae ◽  
Plasmid Content ◽  
Resistance Plasmid

scholarly journals Identification and Sequence of a tet(M) Tetracycline Resistance Determinant Homologue in Clinical Isolates of Escherichia coli

2006 ◽  
Vol 188 (20) ◽  
pp. 7151-7164 ◽  
Author(s):  
C. Hal Jones ◽  
Margareta Tuckman ◽  
Ellen Murphy ◽  
Patricia A. Bradford
Keyword(s):  
Escherichia Coli ◽  
Tetracycline Resistance ◽  
Mobile Element ◽  
Clinical Isolates ◽  
Resistance Determinant ◽  
M Gene ◽  
Insertion Element ◽  
E Coli ◽  
Vibrio Salmonicida ◽  
First Time

ABSTRACT The presence of the tetracycline resistance determinant tet(M) in human clinical isolates of Escherichia coli is described for the first time in this report. The homologue was >99% identical to the tet(M) genes reported to occur in Lactobacillus plantarum, Neisseria meningitidis, and Streptococcus agalactiae, and 3% of the residues in its deduced amino acid sequence diverge from tet(M) of Staphylococcus aureus. Sequence analysis of the regions immediately flanking the gene revealed that sequences upstream of tet(M) in E. coli have homology to Tn916; however, a complete IS26 insertion element was present immediately upstream of the promoter element. Downstream from the termination codon is an insertion sequence that was homologous to the ISVs1 element reported to occur in a plasmid from Vibrio salmonicida that has been associated with another tetracycline resistance determinant, tet(E). Results of mating experiments demonstrated that the E. coli tet(M) gene was on a mobile element so that resistance to tetracycline and minocycline could be transferred to a susceptible strain by conjugation. Expression of the cloned tet(M) gene, under the control of its own promoter, provided tetracycline and minocycline resistance to the E. coli host.

RESULTS OF INTRALESIONAL TRIAMCINOLONE ACETONIDE FOR CHALAZION TREATMENT

2011 ◽  
pp. 100-104
Author(s):  
Thi Thu Nguyen ◽  
Viet Hien Vo ◽  
Thi Em Do
Keyword(s):  
Success Rate ◽  
Key Words ◽  
Triamcinolone Acetonide ◽  
Lower Eyelid ◽  
Upper Eyelid ◽  
Interventional Trial ◽  
The Mean ◽  
First Time

The study use intralesional triamcinolone acetonide injection proceduce for chalazion treatment.1. Objectives: To evaluate results of intralesional triamcinolone acetonide injection for chalazion treatment. 2. Method: This noncomparative prospective interventional trial included 72 chalazions of 61 patients. 3. Results: 61 patients (72 chalazions) with 19 males (31.1%) và 42 females (68.9%), the mean age was 24 ± 9,78 years. 31.1% patients was the first time chalazion and 68.9% patients was more than one times chalazion including 78.6% patients was recurrent at the first position and 21.4% patients occur at new position. 72 chalazions with 16 (22.2%) chalazions was treated before and 56 (77.8%) chalazions wasn’t done that. 72 chalazions with 49 chalazions (68.1%) are local in upper eyelid and 23 chalazions (31.9%) are local in lower eyelid. The mean of chalazion diameter is 6.99 ± 3.03mm. Intralesional triamcinolone acetonide is injected to treat 72 chalazions with 16 (22.2%) chalazions are injected through the route of skin and 56 (77.8%) chalazions are injected through the route of conjunctiva. After 2 weeks follow-up, the success rate was 93.1% and 6.9% failed. 4. Conclusion: intralesional triamcinolone acetonide injection for chalazion treatment is really effective. Key words: chalazion, intralesional triamcinolone acetonide.

Sign in / Sign up

Export Citation Format

Share Document